Topoisomerase I inhibitors for the treatment of brain tumors

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizurnab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.

Original languageEnglish (US)
Pages (from-to)707-716
Number of pages10
JournalExpert review of anticancer therapy
Issue number5
StatePublished - 2008


  • Brain tumor
  • Gliobiastoma
  • Topoisomerase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Topoisomerase I inhibitors for the treatment of brain tumors'. Together they form a unique fingerprint.

Cite this